

Appendix 1: Detailed inclusion/exclusion criteria for each cohort

Tumour Specific Inclusion and Exclusion Criteria

Breast

Inclusion:

- Women aged <50 years old
- Stage 1, 2 or 3 invasive breast cancer
- Have no distant metastases
- Patients due to undergo neoadjuvant treatment should be approached before this starts

For those whose core biopsy shows DCIS only but post-excision biopsy pathology confirms invasive cancer, approach should be made as soon as possible following diagnosis and completion of the baseline questionnaire should be prior to the start of adjuvant treatment.

Exclusion:

- Confirmed diagnosis of CIS (ductal or lobular) only
- Men

Non-Hodgkin Lymphoma

Inclusion:

- Any pathological diagnosis of Diffuse Large B Cell lymphoma (DLBCL) including;
 - Secondary transforming or transformed DLBCL which has transformed from an indolent/low grade lymphoma (most commonly Follicular Lymphoma) as long as the low grade lymphoma was not treated and this is a recent transformation for which curative intent treatment has not yet started.
 - Rare sub-types of DLBCL such as T cell rich Large B Cell Lymphoma and primary mediastinal (thymic) large B-cell lymphoma

Patients who have started steroid pre-phase treatment are eligible for approach before the start of chemotherapy.

Gynaecological cancers

ALL GYNAECOLOGICAL CANCERS

Gynaecological Cancer Exclusion criteria

Synchronous gynaecological primary cancers. For example, synchronous ovarian and endometrial primary cancers.

OVARIAN

Ovarian Inclusion criteria:

Have a confirmed diagnosis either from cytology, histology, imaging or diagnostic primary surgery of either;

- Epithelial ovarian cancer;
 - primary peritoneal cancer
 - fallopian tube cancer
- Ovarian carcinosarcoma
- Granulosa tumour of the ovary

Patients should be entered prior to any treatment including surgery. However, where the diagnosis is only made at the time of surgery, these women may enter the study following surgery. Approach should be made as soon as possible following diagnosis and completion of the baseline questionnaire should occur prior to the start of adjuvant treatment.

| |
|-------------------|
| FIGO stage |
| Stage IA |
| Stage IB |
| Stage IC1 |
| Stage IC2 |
| Stage IC3 |
| Stage IIA |
| Stage IIB |
| Stage IIIA1 |

Ovarian Exclusion criteria:

- Borderline ovarian cancer
- Germ cell tumour
- Sarcoma

ENDOMETRIAL

Endometrial Inclusion criteria:

Have a confirmed diagnosis either from cytology, histology or imaging of;

- endometrial cancer
- endometrial carcinosarcoma

Patients should be entered prior to any treatment including surgery. However, where the diagnosis is only made at the time of surgery, these women may enter the study following surgery. Approach should be made as soon as possible following diagnosis and completion of the baseline questionnaire should occur prior to the start of adjuvant treatment.

| |
|-------------------|
| FIGO stage |
| Stage IA |
| Stage IB |
| Stage II |
| Stage IIIA |
| Stage IIIB |
| Stage IIIC1 |
| Stage IIIC2 |

Endometrial Exclusion criteria

- Choriocarcinoma
 - Germ cell tumour
 - Sarcoma
-

CERVICAL

Cervical Inclusion criteria:

Have a confirmed diagnosis either from cytology, histology or imaging of;

- Cervical cancer

| |
|-------------------|
| FIGO stage |
| Stage IA2 |
| Stage IB1 |
| Stage IB2 |
| Stage IIA1 |
| Stage IIA2 |
| Stage IIB |
| Stage IIIA |
| Stage IIIB |

Cervical Exclusion criteria:

- FIGO stage IA1
 - Cervical carcinoma in situ (CIS)
 - Sarcoma
 - Small cell cancer of the cervix
-

VULVAL

Vulval Inclusion criteria:

Have a confirmed diagnosis either from clinical assessment, cytology, histology, imaging of;

- Vulval cancer

| |
|------------|
| FIGO stage |
| Stage IA |
| Stage IB |
| Stage II |
| Stage IIIA |
| Stage IIIB |
| Stage IIIC |

Vulval Exclusion criteria:

- Basal cell carcinoma
- Melanoma
- Sarcoma
- Vulval intra-epithelial neoplasia (VIN)